Eli Lilly has asked to join in opposing a lawsuit brought by compounding pharmacies against the U.S. Food and Drug ...

After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

Eli Lilly (LLY) is reportedly seeking to oppose a lawsuit filed by compounding pharmacies over the FDA's determination that ...

The FDA has approved Lilly's Zepbound, a glp-1 agonist, for the treatment of sleep apnea, which affects 25 million Americans ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

A new quick-and-easy nasal swab test for kids can diagnose the specific immune system drivers behind their asthma, ...

Encouraging primary care physicians to screen patients for physical inactivity with a simple questionnaire can help identify ...

From PBMs to abortion, there are plenty of health policy issues that will vie for the spotlight in 2025. For pharma marketers ...